AFRO: Ghana, Kenya, and Malawi to participate in malaria vaccine pilot program
WHO is working with the three countries to facilitate regulatory authorization of the Vaccine for use in the pilots through the African Vaccine Regulatory Forum (AVAREF). The malaria vaccine will be administered via intramuscular injection and delivered through the routine national immunization programmes. The World Health Organization Regional Office for Africa (WHO/AFRO) announced today that Ghana, Kenya, and Malawi will take part in a WHO-coordinated malaria vaccine implementation programme (MVIP) that will make the world's first malaria vaccine available in selected areas, beginning in 2018. "The prospect of a malaria vaccine is great news. The injectable vaccine, RTS,S, was developed to protect young children from the most deadly form of malaria caused by Plasmodium falciparum.The malaria vaccine will be administered via intramuscular injection and delivered through the routine national immunization programmes. WHO recommendations and RTS,SRTS,S was developed by GSK and is the first malaria vaccine to have successfully completed a Phase III clinical trial. "The prospect of a malaria vaccine is great news. The injectable vaccine, RTS,S, was developed to protect young children from the most deadly form of malaria caused by Plasmodium falciparum. Brazzaville, 24 April 2017 - The World Health Organization Regional Office for Africa (WHO/AFRO) announced today that Ghana, Kenya, and Malawi will take part in a WHO-coordinated pilot implementation programme that will make the world's first malaria vaccine available in selected areas, beginning in 2018.
collected by :Lucy William
No comments:
Post a Comment